1-4 of 4
Kellie Ryan, MPH
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?

Kellie Ryan, MPH, Hannah Le, PharmD, MPH, Svea K. Wahlstrom, VMD, MS, Kathleen Beusterien, MPH, Oliver Will, PhD, Martine C. Maculaitis, PhD, Thomas W. Leblanc
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–53.
https://doi.org/10.1182/blood-2020-138952
Published: 2020
Journal Articles

Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Jing-Zhou Hou, MD PhD, Kellie Ryan, MPH, Senxi Du, Bruno S. Fang, MD, Stanley M. Marks, MD, Ray Page, Eileen Peng, PharmD, Keith Szymanski, Sharon Winters, Hannah Le, PharmD, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-139951
Published: 2020
Journal Articles

Characteristics of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) Patients Treated with Acalabrutinib in a Real World Setting in the United States

Kellie Ryan, MPH, Chakkarin Burudpakdee, PharmD, Xiaohui Zhao, MS, PhD, Hannah Le, PharmD, MPH, Aimee Near, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3488.
https://doi.org/10.1182/blood-2019-122109
Published: 2019
Journal Articles

Understanding Clinician and Patient Preferences about Novel Agents in Chronic Lymphocytic Leukemia

Hannah Le, PharmD, MPH, Trudy Pendergraft, MSPH, Svea K. Wahlstrom, VMD, MS, Kellie Ryan, MPH, Laura Sarokin, PhD, Emily Mulvihill, MBA, Thomas Campbell, PhD, Martine C. Maculaitis, PhD, Thomas W. LeBlanc, MDMA,MHS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4730.
https://doi.org/10.1182/blood-2019-129606
Published: 2019